证券代码：300550 证券简称：和仁科技 公告编号：2025-003 浙江和仁科技股份有限公司 第四届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江和仁科技股份有限公司（以下简称"公司"）第四届董事会第十次会议 于 2025 年 4 月 22 日以现场表决方式召开。 召开本次会议的通知已于 2025 年 4 月 11 日以电子邮件形式送达各位董事。 本次董事会会议应参与表决董事 7 名，实际参与表决董事 7 名，会议主持人为董 事长赵晨晖先生，本次会议的召集、召开及表决程序符合《公司法》等法律、法 规、规范性文件以及《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议并在议案表决票上签字表决，作出如下决议： 1. 审议通过《关于 2024 年度董事会工作报告的议案》 表决结果： 7 票同意，0 票反对，0 票弃权 公司独立董事向董事会递交了《2024 年度独立董事述职报告》，将在公司 2024 年度股东大会上述职。 表决结果： 7 票同意，0 票反对，0 票弃权 3. 审议通过《关于 202 ...

二、利润分配预案的基本情况 经中汇会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属于上 市公司股东的净利润 39,296,818.30 元 ，合并报表 2024 年度末累计未分配利润 204,332,390.16 元；母公司 2024 年度实现净利润 29,221,319.50 元，根据《公 司章程》规定，按照 2024 年度母公司实现净利润的 10%提取法定盈余公积金 2,922,131.95 元，母公司报表 2024 年度末累计未分配利润 210,984,682.52 元。 出于对投资者持续的回报以及公司长远发展考虑，公司拟定 2024 年度的利 润分配预案为：以未来实施 2024 年年度权益分配方案时股权登记日享有利润分 配、公积金转增股本权利的总股本为基数，向全体股东每 10 股派发现金红利 0.25 元（含税）、不送红股，不以资本公积转增股本。若利润分配方案实施完毕前， 公司股本发生变动，公司将维持每股分配比例不变，相应调整分配总额。 证券代码：300550 证券简称：和仁科技 公告编号：2025-007 浙江和仁科技股份有限公司 2024 年度利润分配预案的公告 本公司及董事会全体成 ...

Financial Performance - The company's revenue for Q1 2025 was ¥78,396,137.81, a decrease of 13.99% compared to ¥91,148,429.82 in the same period last year[5] - The net loss attributable to shareholders was ¥3,844,103.00, representing a significant increase of 645.00% from a loss of ¥515,984.62 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.0146, a decline of 630.00% from -¥0.0020 in the same period last year[5] - Net profit decreased to -¥4,119,299.87 from -¥341,004.41, indicating a significant increase in losses[18] - The total comprehensive income attributable to the parent company was -3,844,103.00, compared to -515,984.62 in the previous period, indicating a significant decline[19] Cash Flow - The net cash flow from operating activities improved by 26.22%, amounting to -¥33,386,117.18 compared to -¥45,250,595.69 in the prior year[5] - Cash inflows from operating activities totaled 64,104,234.14, up from 54,856,404.74 in the previous period[20] - Cash outflows from operating activities decreased to 97,490,351.32 from 100,107,000.43 in the previous period[20] - The net cash flow from investing activities was -16,927,357.81, a decline from 22,495,166.08 in the previous period[20] - Cash inflows from investing activities amounted to 49,492,068.74, compared to 30,003,489.00 in the previous period[20] - Cash outflows from investing activities increased to 66,419,426.55 from 7,508,322.92 in the previous period[20] - The net cash flow from financing activities was -31,137,333.73, worsening from -1,102,776.15 in the previous period[20] - The ending cash and cash equivalents balance was 456,877,114.76, down from 527,265,218.62 in the previous period[20] Assets and Liabilities - Total assets decreased by 2.86% to ¥1,420,322,605.37 from ¥1,462,115,708.52 at the end of the previous year[5] - The company's cash and cash equivalents decreased from ¥542,170,950.15 to ¥460,608,942.25, a decline of approximately 15.0%[14] - Accounts receivable decreased from ¥302,045,937.69 to ¥264,293,020.34, representing a reduction of about 12.5%[14] - Inventory increased from ¥15,837,019.24 to ¥22,897,125.06, showing a growth of approximately 44.3%[14] - Total current assets decreased from ¥1,201,113,121.11 to ¥1,162,590,297.32, a decline of about 3.2%[14] - Total liabilities decreased to ¥304,745,991.69 from ¥342,419,794.97, a reduction of approximately 11%[16] - The company’s total equity attributable to shareholders decreased by 0.35% to ¥1,106,846,526.61 from ¥1,110,690,629.61 at the end of the previous year[5] - The company’s equity attributable to shareholders decreased to ¥1,106,846,526.61 from ¥1,110,690,629.61, a decline of about 0.4%[16] Income and Expenses - Total operating revenue decreased to ¥78,396,137.81 from ¥91,148,429.82, representing a decline of approximately 14.5% year-over-year[17] - Total operating costs decreased to ¥83,707,202.02 from ¥90,767,716.86, a reduction of about 7.4% year-over-year[17] - Research and development expenses increased to ¥15,020,854.32 from ¥11,641,036.77, reflecting a growth of approximately 28.5% year-over-year[17] - The company reported a significant increase of 3477.31% in non-operating income, reaching ¥144,881.00, primarily from asset disposals[9] - The company reported a significant increase in credit impairment losses to ¥2,331,462.86 from a gain of ¥1,480,954.67[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,539, with the top ten shareholders holding a combined 34.34% of the shares[10] - The company reported a total of 243,780 shares under lock-up for executives, with no shares released during the current period[12] Other Financial Metrics - The company's financial expenses decreased by 86.28% to -¥247,884.29, primarily due to reduced interest income[9] - Other income increased by 146.27% to ¥3,121,440.23, mainly attributed to increased software product tax refunds[9] - The company has a significant amount of contract assets totaling ¥370,214,519.63, up from ¥302,818,803.26, indicating an increase of approximately 22.3%[14] - The company’s long-term receivables slightly decreased from ¥8,589,042.33 to ¥8,527,972.28, a decrease of about 0.7%[14] - The company’s trading financial assets increased from ¥20,025,416.66 to ¥30,243,166.66, reflecting a growth of approximately 50.9%[14] - The company’s total non-current assets include long-term equity investments of ¥5,002,753.38, unchanged from the previous period[14] - The company’s total liabilities and equity structure remains stable, with no significant changes reported in the current period[13]

Financial Performance - Heren Technology reported a revenue of RMB 500 million for the fiscal year 2023, representing a year-over-year growth of 15%[20]. - The company achieved a net profit of RMB 80 million, which is an increase of 10% compared to the previous year[20]. - The company's operating revenue for 2024 was ¥406,010,685.79, a decrease of 7.57% compared to ¥439,252,256.21 in 2023[25]. - The net profit attributable to shareholders for 2024 was ¥39,296,818.30, showing a slight increase of 0.46% from ¥39,116,183.90 in 2023[25]. - The net cash flow from operating activities significantly dropped by 90.41% to ¥7,996,955.78 in 2024 from ¥83,375,495.06 in 2023[25]. - The total assets at the end of 2024 increased by 1.65% to ¥1,462,115,708.52 compared to ¥1,438,378,630.67 at the end of 2023[25]. - The net assets attributable to shareholders rose by 2.91% to ¥1,110,690,629.61 at the end of 2024 from ¥1,079,270,615.54 at the end of 2023[25]. - The company reported a basic earnings per share of ¥0.15 for both 2024 and 2023, indicating no change[25]. - The weighted average return on equity for 2024 was 3.59%, a slight decrease from 3.69% in 2023[25]. - Heren Technology's gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management[20]. Dividend Distribution - The company plans to distribute a cash dividend of 0.25 RMB per 10 shares to all shareholders, based on a total of 262,560,141 shares[12]. - For the 2024 profit distribution plan, the company will distribute a cash dividend of 0.25 yuan per 10 shares, totaling approximately 6,564,003.53 yuan based on a share base of 262,560,141 shares[188]. - The cash dividend represents 100% of the total profit distribution amount, indicating a strong commitment to returning value to shareholders[189]. Market Strategy and Expansion - Heren Technology plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[20]. - The company aims to adapt to changes in national policies and macroeconomic conditions by continuing product and technology innovation and strengthening its market position[12]. - The company is actively working to establish a stable customer base by improving service quality and expanding its client resources[7]. - The company is focusing on the development of urban-level smart healthcare solutions, driven by policies such as the integration of medical services, insurance, and pharmaceuticals, which are expected to enhance the market for digital health cities[120][124]. Research and Development - The company is investing RMB 50 million in R&D for new digital health solutions, aiming to launch two new products by Q3 2024[20]. - The number of R&D personnel increased to 257 in 2024 from 247 in 2023, representing a growth of 4.05%[84]. - R&D investment amounted to ¥53,327,497.12 in 2024, accounting for 13.13% of operating revenue, compared to 12.79% in 2023[84]. - The company is developing a SaaS-based clinical information system aimed at improving hospital efficiency, ensuring data security, and enhancing patient care[81]. - A comprehensive SaaS lifecycle management system is in progress to connect patients, healthcare providers, and pharmacies, aiming to reduce costs and improve service quality[82]. Risk Management - The company faces risks related to major project implementation, which could significantly impact current operating performance if any major projects encounter issues[6]. - The company has a high customer concentration, primarily serving large and medium-sized medical institutions, which poses a risk if any major clients decide to terminate their cooperation[7]. - The company recognizes the risk of technology and talent loss in the software industry and is focused on retaining its core technical team through competitive compensation and training[10]. - The company aims to mitigate the risk of major client attrition by improving service quality and maintaining a market-oriented approach to stabilize its customer base[142]. Governance and Internal Control - The company has established a governance structure that ensures the protection of shareholder rights and compliance with relevant laws and regulations[199]. - The internal control system is continuously improved to enhance the company's operational standards[199]. - The company has implemented various measures to protect employee rights and ensure their health and safety[200]. - The company has established an independent financial department with a complete financial accounting system, adhering to the "Enterprise Accounting Standards" and ensuring independent financial decision-making[155]. Operational Challenges - The company is experiencing increased complexity in management control due to the expansion of its service offerings, which may affect its gross profit margin[9]. - The company is facing increased risks in project investment returns due to economic conditions and service fee collection models[113]. - The company has successfully won multiple large-scale projects, each exceeding 10 million yuan, including the Zhejiang Provincial People's Hospital and Gansu Southern Regional Medical Center projects[48]. Employee Management - The total number of employees at the end of the reporting period is 684, with 672 from the parent company and 12 from major subsidiaries[180]. - The total employee compensation for the year is 127.95 million yuan, accounting for 38.19% of the company's total costs[182]. - The company has a training plan aimed at enhancing employee skills and supporting sustainable development[183]. - Continuous investment in human resources is a core strategy, with a focus on effective planning and optimization of personnel allocation[140].

证券代码：300550 证券简称：和仁科技 公告编号：2025-002 浙江和仁科技股份有限公司 关于已披露日常经营合同收到中标通知书 的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江和仁科技股份有限公司（以下简称"和仁科技"或"公司"）于 2025 年 4 月 7 日披露了《关于日常经营合同预中标的提示性公告》（详见巨潮资讯网 http://www.cninfo.com.cn，公告编号：2025-001），公司近日收到新疆维吾尔 自治区政务服务和公共资源交易中心发出的《中标（成交）通知书》，和仁科技 被确定为"新疆维吾尔自治区中医医院智慧医院信息化建设项目"的中标人。 一、中标项目情况 浙江和仁科技股份有限公司董事会 2025 年 4 月 10 日 1、项目名称：新疆维吾尔自治区中医医院智慧医院信息化建设项目 2、采购人：新疆维吾尔自治区中医医院 3、采购代理机构：新疆维吾尔自治区政务服务和公共资源交易中心 4、项目中标金额报价：148,160,000 元。实际金额依据双方后续签订的合 同为准。 二、中标对公司的影响 若公司能顺利签订合同并且 ...

证券时报网讯，企查查APP显示，近日，浙江和众仁信科技有限公司成立，法定代表人为赵晨晖，注册 资本1亿元，经营范围包含：互联网数据服务；信息系统集成服务；数据处理服务；物联网技术服务； 物联网技术研发等。 企查查股权穿透显示，该公司由和仁科技等共同持股。 ...

二、董事会会议审议情况 经与会董事审议并在议案表决票上签字表决，审议通过如下议案： 1、审议通过《关于制定公司<舆情管理制度>的议案》 表决结果：7 票同意，0 票反对，0 票弃权 证券代码：300550 证券简称：和仁科技 公告编号：2024-043 浙江和仁科技股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江和仁科技股份有限公司（以下简称"公司"）第四届董事会第九次会议 于 2024 年 12 月 30 日以通讯表决方式召开。 召开本次会议的通知已于 2024 年 12 月 25 日以电子邮件形式送达各位董事。 本次董事会会议应出席董事 7 名，实际出席董事 7 名。会议由公司董事长赵晨晖 主持。会议的召集、召开及表决程序符合《公司法》等法律、法规、规范性文件 以及《公司章程》的有关规定。 《舆情管理制度》详见信息披露网站巨潮资讯网（http://www.cninfo.com.cn）。 三、备查文件 1、经与会董事签字并加盖董事会印章的董事会决议； 2、深交所要求的其他文件。 特此公 ...

浙江和仁科技股份有限公司 舆情管理制度 第一章 总则 第一条 为了提高浙江和仁科技股份有限公司 以下简称 公司"）应对各类 舆情的能力，建立快速反应和应急处置机制，及时妥善处理各类舆情对公司股价、 公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权益，根据 《深圳证券交易所创业板股票上市规则》和 《公司章程》等相关规定，特制订本 制度。 第二条 本制度所称舆情包括： 一）报刊、电视、网络等媒体对公司进行的报道； 二）社会上存在的已经或将给公司造成影响的传言或信息； 三）其他涉及公司信息披露且可能或者已经影响社会公众投资者投资取向， 造成股价异常波动的信息。 第二章 舆情管理的组织体系及其工作职责 第三条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对。 第四条 公司成立舆情管理工作领导小组 以下简称 舆情工作组"），由公 司董事长任组长，董事会秘书担任副组长，成员由公司其他高级管理人员及相关 职能部门负责人组成。 第五条 舆情工作组是公司应对各类舆情处理工作的领导机构，统一领导公 司应对各类舆情的处理工作，就相关工作做出决策和部署，根据需要研究决定公 司对外发布信息，主要工作职责包括： ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥103,854,630.35, representing a slight increase of 0.11% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was ¥15,261,850.34, a decrease of 1.00% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥14,913,618.66, down 1.94%[3]. - Year-to-date net profit attributable to shareholders decreased by 92.92% to ¥929,244.29, with a year-to-date revenue decline of 6.42% to ¥264,317,028.74[3]. - Total operating revenue for Q3 2024 was CNY 264,317,028.74, a decrease of 6.4% compared to CNY 282,449,005.28 in the same period last year[13]. - Net profit for Q3 2024 was CNY 522,947.40, significantly lower than CNY 13,004,310.86 in Q3 2023, indicating a decline in profitability[14]. - The total comprehensive income attributable to the parent company for Q3 2024 is CNY 929,244.29, a decrease from CNY 13,115,994.73 in the previous period[15]. Cash Flow and Liquidity - The company's cash flow from operating activities showed a net outflow of ¥115,425,086.86, a decrease of 20.33% compared to the previous year[3]. - The net cash flow from operating activities for Q3 2024 is -CNY 115,425,086.86, compared to -CNY 95,927,471.87 in the same period last year[17]. - Cash inflow from operating activities totaled CNY 131,808,331.68, down from CNY 252,632,718.17 in the previous year[17]. - Cash outflow from operating activities reached CNY 247,233,418.54, a decrease from CNY 348,560,190.04 year-over-year[17]. - As of September 30, 2024, the company's cash and cash equivalents amounted to ¥482,414,027.65, a decrease from ¥555,323,304.95 at the beginning of the period, representing a decline of approximately 13.1%[11]. - The cash and cash equivalents at the end of Q3 2024 amounted to CNY 476,886,509.12, compared to CNY 412,296,423.36 at the end of the previous year[17]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥1,435,932,726.15, reflecting a decrease of 0.17% from the end of the previous year[3]. - The total assets decreased slightly to CNY 1,435,932,726.15 from CNY 1,438,378,630.67, reflecting a stable asset base[13]. - The total liabilities decreased to CNY 353,013,879.33 from CNY 357,905,927.02, indicating a reduction in financial obligations[13]. - The company's equity attributable to shareholders decreased by 0.64% to ¥1,072,323,055.60 compared to the end of the previous year[3]. - The company's equity attributable to shareholders decreased to CNY 1,072,323,055.60 from CNY 1,079,270,615.54, reflecting the impact of lower profits[13]. Investments and Expenses - The company reported a significant increase in prepayments, which rose by 461.21% to ¥9,261,272.84, attributed to increased procurement payments[6]. - The company’s long-term equity investments surged by 165,945.17% to ¥3,166,049.62 due to increased investment in Zhongyuan Heren[6]. - The company experienced a 1557.92% increase in credit impairment losses, amounting to -¥22,538,003.98, primarily influenced by sales collection issues[6]. - The company reported a decrease in financial expenses by 53.33% to -¥4,025,806.35, mainly due to reduced interest income[6]. - Research and development expenses increased to CNY 38,564,331.96 from CNY 37,478,001.90, highlighting continued investment in innovation[14]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 9,299, with the largest shareholder, Tongce Medical Co., holding 19.01% of shares[8]. - The company reported a total of 295,230 restricted shares at the beginning of the period, with 51,450 shares released from restrictions during the period[9]. - The largest shareholder, Tongce Medical Co., held 49,920,315 shares, representing 19.01% of the total shares[8]. - The company has a total of 40,260,815 shares held by Hangzhou Panyuan Investment Co., accounting for 15.33% of the total shares[8]. Operational Changes - The company terminated the "Smart Hospital Integrated Construction Project" and will permanently supplement the remaining raised funds into working capital, following approval at the September 9, 2024, shareholders' meeting[10].

证券代码：300550 证券简称：和仁科技 公告编号：2024-042 浙江和仁科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江和仁科技股份有限公司（以下简称"公司"）为真实、准确、客观反映 公司的财务状况和经营成果，根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《企业会计准则》等相关规定，公司本着谨 慎性原则，对合并财务报表范围内的各项需要计提减值的资产进行了评估和分 析，对预计存在可能发生减值损失的相关资产计提减值准备。现将相关情况公告 如下： 一、本次计提减值准备的情况概述 关于 2024 年 1-9 月计提资产减值准备的公告 （一）、本次计提资产减值准备的原因 根据《企业会计准则》和公司会计政策的相关规定，公司对合并范围内截止 2024 年 9 月 30 日的各类资产进行了清查、分析和评估，对部分可能发生信用、 资产减值的资产计提了减值准备。 （二）、本次计提资产减值准备的情况 公司及下属子公司对 2024 年 9 月末存在可能发生减值迹象的资产进行全面 清查和资产减值测试后，计提 2024 年 ...